In COVID-19 patients, mononuclear cell PD-L1 transcript levels (3) and CD4+ T-cell surface PD-1 protein levels (4) are increased, possibly reflective of an evolving immunosuppressive response conducive to ICI therapy. The gene discussed is CD274; the disease is COVID-19.